Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, August 19 at 2:00 PM EDT

Register Free →

Search

Top

Back to Contracts

Compound Handling and Dilution Preparation

Active

Federal

Response Deadline08/24/2026, 12:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The contract requires the recipient to receive a test compound in the form of a 1000x DMSO stock solution and precisely prepare an 8-point, 3-fold dilution series for utilization in the PRISM assay. The preparation must ensure the stability of the compounds throughout the dilution process and maintain full traceability of each step to guarantee experimental reproducibility and data integrity. All procedures must adhere to standardized protocols to avoid contamination, degradation, or measurement errors that could compromise assay outcomes. The work is classified as a subcontract under NAICS code 325412 and is issued by the National Institutes of Health under the Department of Health and Human Services. The solicitation was posted on August 7, 2026, with a response deadline of August 24, 2026. The performance location and specific contact details are not provided, but the scope is strictly focused on compound handling and serial dilution preparation without additional responsibilities such as assay execution or data analysis. Accurate documentation, quality control measures, and compliance with good laboratory practices are implicitly required to meet the contract’s technical objectives.

General Info

Prepare 8-point 3-fold dilution series from 1000x DMSO stock for PRISM assay with full traceability and quality control.

Agency

Department Of Health And Human Services → National Institutes Of Health OlaoView Agency

NAICS

325412 - Pharmaceutical Preparation ManufacturingView NAICS

Place of Performance

MD

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PostedAug 7

subcontract

Response DeadlineAug 24

Submission deadline

Response Deadline

08/24/2026, 12:00:00 PM UTCin 16 days

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more

AgencyDepartment Of Health And Human Services → National Institutes Of Health Olao

ContactsNo contacts available

OfficeN/A

Organization / Agency

Department Of Health And Human Services → National Institutes Of Health Olao

View Agency Profile

Office AddressN/A

ContactsNo contact information available

Full Description

Show more

Receive the test compound as a 1000x DMSO stock and prepare an accurate 8-point, 3-fold dilution series for use in the PRISM assay, ensuring stability and traceability.

Similar Contracts

Same NAICS industry code

Unit-Dose Pharmaceutical Repackaging ServicesThe contract seeks a subcontractor to repackage bulk prescription medications into unit-dose or unit-of-use formats with full compliance to FDA standards, including accurate labeling, serialization, and verification of packaging integrity. The work involves precise handling of pharmaceuticals to ensure patient safety, regulatory adherence, and traceability throughout the repackaging process. All operations must meet stringent quality controls to maintain the integrity of medication distribution within healthcare settings. Performance of this subcontract is required at the location in Leavenworth, Kansas, with a zip code of 66048, and is issued under the NAICS code 325412, which corresponds to pharmaceutical and medicine manufacturing. The opportunity is associated with the Department of Veterans Affairs through the National Cmop Office and is classified as a subcontract under a larger procurement initiative. Interested parties must submit responses by August 21, 2026, at 10:00 PM Eastern Time, with the solicitation posted on August 7, 2026. No set-aside designation or organizational type restrictions are specified.

National Cmop Office (36C770)

POSTED

DEADLINE

Molecular Diagnostic Reagent Supply – Cepheid GeneXpert Test KitsThe contract is for the supply and delivery of Cepheid GeneXpert molecular diagnostic reagent kits used in infectious disease testing, requiring strict adherence to cold-chain logistics to ensure product integrity and full compliance with regulatory standards. The reagents are essential for rapid, accurate diagnostic screening and must be delivered reliably to a designated performance location in Lawton, Oklahoma, with zip code 73507. This subcontract is reserved under the Indian Small Business Economic Enterprise set-aside program, specifically targeting qualified Indian small businesses to foster economic development within tribal communities. The NAICS code 325412 classifies the procurement within the pharmaceutical and medicinal chemical manufacturing sector, aligning with the Indian Health Service’s mission under the Department of Health and Human Services to enhance healthcare access and outcomes for Native populations. All bids must be submitted by the deadline of August 14, 2026, to ensure eligibility, and the award will emphasize capability in handling sensitive medical supplies under stringent environmental and compliance controls.

Indian Health Service

POSTED

DEADLINE

Custom Organic Compound Synthesis (Non-GMP)The contract involves the custom synthesis of five small-molecule compounds, each in quantities of five grams, for use in Ewing sarcoma drug development under non-GMP research conditions. The work encompasses the full scope of organic synthesis including route design, multi-step chemical reactions, and purification to yield chemically defined products suitable for preclinical evaluation. All activities are non-GMP, meaning the compounds will not be produced under regulatory quality systems required for clinical use but rather for internal research and biological testing purposes. The effort is structured as a subcontract under the National Institutes of Health, operating through the Department of Health and Human Services, with the NAICS code 325412 indicating pharmaceutical and medicine manufacturing. The solicitation was posted on August 7, 2026, and responses are due by August 24, 2026, with no set-aside designation applied. The place of performance and point of contact details are not specified, and the work is expected to be carried out by an external research or synthesis provider aligned with the NIH’s oncology drug discovery goals.

National Institutes Of Health Olao

POSTED

DEADLINE

High-Priority Pathogen Infection PreventionThe contract seeks preventive solutions non-vaccine approaches to combat infections caused by high-priority pathogens including Pseudomonas aeruginosa and Shigella, targeting urgent public health and defense-related threats. It is issued under the Defense Health Agency within the Department of Defense and is classified as a subcontract, with the North American Industry Classification System code 325412 indicating focus on pharmaceutical preparation manufacturing. The initiative aims to advance innovative, non-pharmaceutical interventions such as antimicrobial barriers, prophylactic agents, or environmental controls that interrupt transmission or reduce pathogen load without relying on vaccines. Responses are due by October 30, 2026, and the performance location is designated as Frederick, though the full address and point of contact details are not provided. The solicitation remains open to qualified entities capable of delivering scalable, evidence-based preventive technologies aligned with military and civilian health protection needs.

Defense Health Agency

POSTED

DEADLINE

Burn and Complex Wound Care SolutionsThe contract titled Burn and Complex Wound Care Solutions seeks advanced wound care technologies specifically designed for the treatment of burns and combat-related injuries, with eligibility contingent upon exclusion criteria outlined in the final Request for Proposals. It is issued under the NAICS code 325412, indicating a focus on pharmaceutical and medical manufacturing, and is structured as a subcontract within the Department of Defense, managed by the Defense Health Agency. The opportunity was posted on August 7, 2026, with a response deadline of October 30, 2026, and performance is expected to center in Frederick, though the exact location details are unspecified. The solicitation does not designate a specific set-aside status, and all interested parties must ensure their solutions meet the technical and clinical standards required for military medical applications while adhering to any final exclusions defined in the RPP.

Defense Health Agency

POSTED

DEADLINE

Non-Addictive Battlefield Pain Management SolutionsThe contract seeks the development of non-opioid analgesics or alternative pain relief technologies designed for military use in austere environments, with a focus on creating effective, non-addictive solutions that can be deployed in combat or field conditions where traditional pain management options are impractical or risky. The work must address the unique challenges of battlefield medicine, including limited resources, extreme climates, and the need for rapid, reliable pain control without the potential for dependency or misuse. The technology must be robust, easily transportable, and compatible with existing military medical protocols and equipment. The contract is structured as a subcontract under the Defense Health Agency, part of the Department of Defense, and is governed by the NAICS code 325412 for pharmaceutical preparation manufacturing. Proposals must be submitted by October 30, 2026, and performance will center in Frederick, with no specific city, state, or zip provided beyond that location. There is no set-aside classification applied to this opportunity, and while no point of contact is listed, interested parties can access additional details through the provided SAM.gov link. The initiative reflects a strategic priority to reduce reliance on opioid-based treatments in military healthcare and advance innovations that enhance soldier readiness and long-term health outcomes.

Defense Health Agency

POSTED

DEADLINE

Library of Pharmacologically Active Compounds (LOP

Solicitation # 75N98026Q00991

The National Institutes of Health, Office of the Director, Office of Acquisitions, is soliciting proposals under solicitation number 75N98026Q00991 for the Library of Pharmacologically Active Compounds (LOPAC), conducted as a commercial item acquisition under FAR Subpart 12.6. This is an unrestricted, full and open competition with no set-aside, targeting vendors capable of delivering a defined set of pharmacologically active compounds as 1000x stock solutions in 100% DMSO for use in a broad cancer cell line screening study via the PRISM platform. The contract is a Firm-Fixed-Price type, with an estimated value not to exceed the simplified acquisition threshold of $250,000, and the NAICS code 325412 applies with a small business size standard of 1,300 employees. All offerors must be actively registered in the System for Award Management with a valid Unique Entity Identifier and Taxpayer Identification Number, and must certify their business size status. Proposals must include pricing details, shipping and handling costs, delivery timeframe, F.O.B. destination, and product catalog numbers, submitted electronically to Jaddua.Johnston@nih.gov by 8:00 AM EST on August 24, 2026. Performance is required to begin on September 4, 2026, with an end date of December 3, 2026, and deliverables include cell line viability data, assay quality control metrics, univariate and multivariate feature correlation analyses, and all raw data generated from screening activities, to be submitted through the PRISM Portal approximately four months after the submission window closes. The government will provide the test compound and expects full compliance with the PRISM assay protocol using an 8-point, 3-fold dilution series in a 5-day Luminex-format assay. Packaging must meet commercial standards, with no military specifications or labeling requirements beyond shipment in 100% DMSO to NIH/NCATS at 9808 Medical Center Drive, Rockville, MD 20850. Invoices must be submitted electronically via the Invoicing Processing Platform (IPP). Evaluation will be based on price, technical capability, past performance, and delivery schedule, with award going to the offeror providing the best value to the government through a trade-off process, not necessarily the lowest price. All

National Institutes Of Health Olao

POSTED

DEADLINE

Government Contracting Compliance & GSA Schedule SupportThe contract solicits the supply of biotechnology reagents through existing GSA Schedule or GWAC vehicles, requiring full compliance with the Federal Acquisition Regulation for pricing and delivery terms. All offerings must leverage pre-negotiated, FAR-compliant contractual mechanisms to ensure transparency, affordability, and efficiency in procurement by the National Institutes of Health, specifically the National Institute on Drug Abuse under the Department of Health and Human Services. The NAICS code 325412 confirms the primary focus on pharmaceutical and biological product manufacturing, indicating the need for high-purity, research-grade reagents suitable for scientific and clinical applications. Responses must be submitted by August 13, 2026, and the contract is structured as a subcontract, implying the awardee will fulfill obligations under a prime contract holder rather than directly with the government. Performance is expected to align with federal supply chain standards, though no specific place of performance or set-aside criteria are provided. Compliance with GSA Schedule or GWAC terms is mandatory, ensuring that pricing remains consistent with established federal rates and that delivery timelines meet agency operational needs. The solicitation underscores the importance of proven regulatory adherence and reliable supply chain execution to support critical biomedical research activities.

National Institutes Of Health Nida

POSTED

DEADLINE

Specialty Biotech Reagent Manufacturing (dCODE Dextramer®)The contract involves the manufacture of specialized immunology reagents based on dextramer technology, specifically customizable HLA-peptide complexes equipped with fluorescent barcoding, intended for use in research and clinical applications. These reagents are designed to enable precise detection and analysis of antigen-specific T cells, supporting advancements in immunological studies and potential therapeutic development. The production must meet stringent quality and consistency standards to ensure reliability across diverse experimental and diagnostic settings, with an emphasis on scalability and customization to accommodate varying peptide and HLA combinations. This is a subcontract under the National Institutes of Health, specifically the National Institute on Drug Abuse, part of the Department of Health and Human Services, with the NAICS code 325412 indicating biological product manufacturing. The opportunity was posted on August 6, 2026, and responses are due by August 13, 2026, with no set-aside classification specified. The place of performance and other location details are not provided, indicating flexibility in where the manufacturing may occur, though all work must comply with the technical and regulatory requirements for clinical-grade reagents. The focus is squarely on advanced biotech manufacturing capabilities, emphasizing precision, reproducibility, and compliance with industry best practices for immune monitoring tools.

National Institutes Of Health Nida

POSTED

DEADLINE

Supplier of Universal 5' Gene Expression Kits

National Institutes Of Health Nida

POSTED

DEADLINE

Supplier of Feature Barcode Kits for Single-Cell Analysis

National Institutes Of Health Nida

POSTED

DEADLINE

Supplier of Chromium GEM-X Single Cell 5' Chip Kits

National Institutes Of Health Nida

POSTED

DEADLINE

More opportunities from Department Of Health And Human Services → National Institutes Of Health Olao

Same awarding agency

Laboratory Animal Supply and Acclimation

Other Chemical and Allied Products Merchant Wholesalers

POSTED

DEADLINE

Preclinical Data Management and Reporting

Administrative Management and General Management Consulting Services

POSTED

DEADLINE

Necropsy and Tissue Preservation Services

Administrative Management and General Management Consulting Services

POSTED

DEADLINE

Dose Formulation and Compound Handling

Research and Development in Biotechnology

POSTED

DEADLINE

Preclinical Rodent Toxicity Study Execution

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Regulatory and Data Compliance SupportThe contract titled Regulatory and Data Compliance Support is a subcontract issued by the National Institutes of Health under the Department of Health and Human Services, focused on ensuring all study documentation, raw data, and final reports adhere to Federal Acquisition Regulation standards, applicable data rights provisions, strict confidentiality protocols, and government audit requirements. The work is intended to support compliance across the full lifecycle of research activities, mandating rigorous documentation practices and secure data handling procedures to meet federal oversight standards. The solicitation was posted on August 7, 2026, with a response deadline of August 24, 2026, and is classified under NAICS code 541611 for administrative management and general management consulting services. The place of performance and point of contact details are not specified, but performance is expected to align with federal guidelines regardless of location, and interested parties must submit proposals before the deadline to be considered for award.

Administrative Management and General Management Consulting Services

POSTED

DEADLINE

Pharmacokinetic Data Analysis and ReportingThe contract entails the analysis of plasma concentration-time data to determine pharmacokinetic parameters and generate detailed concentration-time curves, with all results delivered in a structured Excel report accompanied by a narrative summary that interprets the findings. The work is focused on quantitative evaluation of drug behavior in the body, requiring precise computational methods and regulatory-compliant reporting standards to ensure accuracy and reproducibility. The deliverables must be clearly formatted, scientifically sound, and tailored for use in regulatory submissions or internal R&D decision-making. This is a subcontract under the National Institutes of Health, operating through the Department of Health and Human Services, with the NAICS code 541690 indicating specialized scientific and technical consulting services. The opportunity was posted on August 7, 2026, with a response deadline of August 24, 2026, and no set-aside provisions are specified. While the place of performance and point of contact details are not provided, the work is expected to be performed remotely or under flexible arrangements, consistent with the nature of data analysis tasks. The contracting entity is seeking qualified contractors with demonstrated expertise in pharmacokinetic modeling and data reporting to support ongoing research initiatives.

Other Scientific and Technical Consulting Services

POSTED

DEADLINE

Bioanalytical Assay Development and QuantificationThe contract requires the development and performance of liquid chromatography-tandem mass spectrometry assays to quantify plasma concentrations of three small-molecule inhibitors and their metabolite 1-MNA in mouse plasma samples. The work involves establishing validated methods for accurate and precise measurement of these compounds, ensuring reliability for preclinical pharmacokinetic studies. The assays must be capable of detecting low concentrations with appropriate sensitivity, specificity, and reproducibility across the expected concentration range in biological matrices. This subcontract is issued under the NAICS code 541380, indicating a focus on scientific and technical consulting services, and is associated with the National Institutes of Health under the Department of Health and Human Services. The solicitation was posted on August 7, 2026, with a response deadline of August 24, 2026. The place of performance and specific location details are not provided, and no set-aside provisions are specified. The work is intended to support biomedical research activities, likely aimed at evaluating drug metabolism and exposure profiles in mouse models.

Testing Laboratories and Services

POSTED

DEADLINE

Preclinical Pharmacokinetic (PK) Study ExecutionThe contract involves the execution of preclinical pharmacokinetic studies in mice to evaluate the absorption, distribution, metabolism, and excretion of three lead compounds following both intravenous and oral administration. Blood samples will be collected at ten distinct time points across a 24-hour period to generate detailed concentration-time profiles for each compound, enabling the calculation of key pharmacokinetic parameters such as bioavailability, clearance, and half-life. The work is to be performed under a subcontract arrangement with the National Institutes of Health, operating under the Department of Health and Human Services, and is classified under NAICS code 541940 for other scientific and technical consulting services. The solicitation was posted on August 7, 2026, with a response deadline of August 24, 2026, and the studies are expected to be conducted at an unspecified location designated by the contracting entity. The scope requires strict adherence to standardized protocols for animal handling, sample processing, and data collection to ensure regulatory compliance and scientific rigor.

Veterinary Services

POSTED

DEADLINE

Confidential Research Reporting and AnalysisThe contract requires the generation of detailed scientific reports focused on univariate and multivariate correlation analyses of drug response patterns across a panel of cell lines, ensuring rigorous analytical standards and adherence to strict confidentiality protocols. All work must comply with NCATS publication restrictions, meaning results cannot be publicly disclosed or published without explicit authorization, and all data handling must preserve the proprietary and sensitive nature of the underlying biological and pharmaceutical information. The project is structured as a subcontract under the National Institutes of Health, operating within the Department of Health and Human Services, with the NAICS code 541715 indicating it falls under scientific research and development services. The solicitation was posted on August 7, 2026, with a response deadline of August 24, 2026, and performance is expected to be carried out under the oversight and guidelines of the NCATS program, though no specific location or point of contact is provided.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Data Management and Portal SubmissionThe contract requires the compilation, validation, and secure submission of raw viability data, quality metrics, and analytical outputs through the PRISM Portal within four months after study completion, with strict adherence to specified formatting standards to ensure compliance and data integrity. All submissions must be transmitted securely and meet predefined technical requirements to facilitate accurate processing and regulatory alignment. This subcontract, posted by the National Institutes of Health under the Department of Health and Human Services with a NAICS code of 541611, is open for response until August 24, 2026, and focuses on data management activities supporting federal research initiatives. While no set-aside type is designated, the performance location and point of contact details are unspecified, indicating that the work may be conducted remotely or at the contractor’s discretion, provided all submission deadlines and portal protocols are strictly followed.

Administrative Management and General Management Consulting Services

POSTED

DEADLINE

PRISM Pooled Cancer Cell Line Assay ExecutionThe contract calls for the execution of a 5-day Luminex-format viability assay using the PRISM platform to evaluate a compound’s effect across approximately 900 barcoded cancer cell lines. The assay will utilize an 8-point, 3-fold dilution series to generate dose-response data, enabling precise measurement of cellular viability under varying concentrations of the compound. All work must be conducted with high technical rigor to ensure the generation of high-quality, reproducible viability data suitable for downstream analysis. The deliverables include comprehensive viability profiles for each cell line and detailed correlation analyses that link compound sensitivity to cellular and genetic characteristics across the panel. The project is structured as a subcontract under the National Institutes of Health, part of the Department of Health and Human Services, with the North American Industry Classification System code 541715 indicating it falls under research and development in the physical, engineering, and life sciences. The solicitation was posted on August 7, 2026, and responses are due by August 24, 2026.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE